EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Clinical and Translational Allergy

Nikolaos Papadopoulos^2,28  Ulrich Wahn^1,19  Johannes C Virchow^4,45  Marianne van Hage^3,36  Erkka Valovirta^4,43  Gabriela Senti^4,41  Gianenrico Senna^1,18  Sabina Rak^1,10  Oliver Pfaar^1,13  Giovanni Passalacqua^1,11  Giovanni Pajno^3,34  Bodo Niggemann^1,15  Antonella Muraro^3,30  Ralph Mosges^3,35  Carmen Moreno^1,12  Jan Lötvall^2,23  Ludger Klimek^1,13  Jörg Kleine-Tebbe^2,24  Marek Jutel^2,25  Lars Jacobsen⁶  Montserrat Fernandez-Rivas²  Peter Eng^3,37  Stephen R Durham^2,20  Alain Didier^2,29  Ronald Dahl^3,31  Victoria Cardona^3,32  Walter G Canonica^2,26  Albrecht Bufe^2,27  Barbara Bohle^3,33  Emilio Alvarez-Cuesta^3,38  Eva M Varga^4,44  Carmen Vidal⁸  Jocelyne Just^1,16  Cezmi Akdis³  Antonio Nieto^4,40  Beatrice Bilo^1,17  Rudolph Valenta⁵  Hans J Malling⁴  Claus Bachert⁹  Glenis Scadding^3,39  Anthony Frew^1,14  Aziz Sheikh¹  Jean Bousquet^4,42  Roy Gerth van Wijk^2,22  Pascal Demoly⁷  Moises A Calderon^2,21 

[1] The University of Edinburgh, Centre for Population Health Sciences, Edinburgh, UK;Hospital Clínico San Carlos, Facultad de Medicina-UCM, IdISSC, Madrid, Spain;Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland;Allergy Clinic, National University Hospital, Copenhagen, Denmark;Division of Immunopathology, Department of Pathophysiology and Allergy Research, Centre for Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Vienna, Austria;Research Centre for Prevention and Health, Glostrup University Hospital, Copenhagen, Denmark;Department and INSERM U657, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France;Department of Allergy, Hospital Clinico Universitario, Santiago de Compostela, Spain;Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium;Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Goteborg, Sweden;Allergy and Respiratory Diseases, University of Genoa, Genoa, Italy;Seccion de Alergia, Hospital Reina Sofía, Cordoba, Spain;Center for Rhinology and Allergology, Wiesbaden, Germany;Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, UK;Pediatric Allergology and Pneumology, German Red Cross Clinic Westend, Berlin, Germany;Centre de l'Asthme et des Allergies, Hôpital d'enfant Armand Trousseau, Paris, France;Department of Internal Medicine, Immunology, Allergy & Respiratory Diseases, University Hospital, Ospedali Riuniti di Ancona, Ancona, Italy;Allergy Service, Verona General Hospital, Verona, Italy;Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany;Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London, United Kingdom;Section of Allergy and Clinical Immunology, Imperial College, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK;Department of Allergology, Erasmus MC-University Medical Center, Rotterdam, The Netherlands;Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Allergy & Asthma Center Westend, Outpatient Clinic Hanf, Ackermann & Kleine-Tebbe, Berlin, Germany;Department of Clinical Immunology, Wroclaw Medical University, Wrocław, Poland;Allergy and Respiratory Diseases Clinic, Department of Internal Medicine, University of Genoa, Genoa, Italy;Department of Experimental Pneumology, Ruhr-University, Bochum, Germany;UPC Research Laboratories, Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece;Service de Pneumologie-Allergologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France;Department of Pediatrics, Padua General Hospital, Padua, Italy;Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, C, 8000, Denmark;Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain;Department of Pathophysiology and Allergy Research, Christian Doppler Laboratory for Immunomodulation, Medical University of Vienna, Vienna, Austria;Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy;Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), Medical Faculty, University at Cologne, Cologne, Germany;Division of Respiratory Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden;Allergy Unit, Children’s Hospital, Kantonsspital Aarau, Switzerland;Allergy Division, Ramon & Cajal University Hospital, Alcala de Henares University, Madrid, Spain;The Royal National Throat, Nose and Ear Hospital, London, UK;Pediatric Allergy and Pneumology Unit, Children's Hospital La Fe, Valencia, Spain;Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland;Allergy Department and INSERM U657, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France;Suomen Terveystalo Allergy Clinic, Turku, Finland;Department of Paediatrics, Respiratory and Allergic Disease Division, Medical University Graz, Graz, Austria;Department of Pulmonology, Intensive Care Medicine, Zentrum f. Innere Medizin, Klinik I, University Clinic Rostock, Rostock, Germany

关键词: Quality of life;    Health economics;    Immunotherapy;    Rhinitis;    Asthma;    Allergy;   

Others  :  794513
DOI  :  10.1186/2045-7022-2-20

 received in 2012-09-24, accepted in 2012-10-09,  发布年份 2012

【 摘 要 】

Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.

Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.

Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals’ quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.

Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.

We call upon Europe’s policy-makers to coordinate actions and improve individual and public health in allergy by:

Promoting awareness of the effectiveness of allergen specific immunotherapy

Updating national healthcare policies to support allergen specific immunotherapy

Prioritising funding for allergen specific immunotherapy research

Monitoring the macroeconomic and health economic parameters of allergy

Reinforcing allergy teaching in medical disciplines and specialties

The effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.

【 授权许可】

   
2012 Calderon et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.; ISAAC Phase Three Study Group. Lancet 2006, 368(9537):733-743.
• [2]Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al.: Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007, 62:758-766.
• [3]Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P: Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy 2012, 67:91-98.
• [4]Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al.: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).; World Health Organization; GA(2)LEN; AllerGen. Allergy 2008, 63(Suppl 86):8-160.
• [5]Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al.: The diagnosis and management of rhinitis: an updated practice parameter. Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2008, 122(2 Suppl):S1-S84.
• [6]World Health Organization (WHO): Fact sheet No. 307 on Asthma. 2011.
• [7]Punekar YS, Sheikh A: Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices. Clin Exp Allergy 2009, 39(8):1209-1216.
• [8]Isolauri E, Huurre A, Salminem S, Impivaara O: The allergy epidemic extends beyond the past two decades. Clin Exp Allergy 2004, 34:1007-1010.
• [9]Gupta R, Sheikh A, Strachan DP, Anderson HR: Time trends in allergic disorders in the UK. Thorax 2007, 62(1):91-96.
• [10]Grize L, Gassner M, Wüthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, et al.: Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5–7-year old Swiss children from 1992 to 2001. Allergy 2006, 61(5):556-562.
• [11]Smith JA, Drake R, Simpson A, Woodcock A, Pickles A, Custovic A: Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med 2008, 177(12):1358-1363.
• [12]Anandan C, Nurmatov U, van Schayck OC, Sheikh A: Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010, 65(2):152-167.
• [13]Siroux V, Boudier A, Anto JM, Cazzoletti L, Accordini S, Alonso J, et al.: Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study. Allergy 2008, 63(5):547-554.
• [14]Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. J Allergy Clin Immunol 2007, 120:381-387.
• [15]Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M, et al.: Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006, 117:158-162.
• [16]Stuck BA, Czaijkowski J, Hagner AE, Klimek L, Verse T, Hörmann K, et al.: Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 2004, 113:663-668.
• [17]Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ, et al.: ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy 2008, 63(6):660-669.
• [18]Bachert C, Bousquet J, Canonica GW, Durham SR: The XPERTTM study group. XPERTTM Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004, 114:838-844.
• [19]Virchow JC, Kay S, Demoly P, Mullol J, Canonica W, Higgins V: Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ. 2011, 14(3):305-314.
• [20]Wertz DA, Pollack M, Rodgers K, Bohn RL, Sacco P, Sullivan SD: Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol. 2010, 105(2):118-123.
• [21]Lefevre F, Moreau D, Sémon E, Kalaboka S, Annesi-Maesano I, Just J: Maternal depression related to infant's wheezing. Pediatr Allergy Immunol. 2011, 22(6):608-613.
• [22]Gupta R, Sheikh A, Strachan DP, Anderson HR: Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004, 34(4):520-526.
• [23]Anandan C, Gupta R, Simpson CR, Fischbacher C, Sheikh A: Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med. 2009, 102(10):431-442.
• [24]European Respiratory Society (ERS): European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. 2003.
• [25]Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C, et al.: The socio-economic burden of asthma is substantial in Europe. Allergy 2008, 63(1):116-124.
• [26]Sullivan SD, Turk F: An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008, 63:670-684.
• [27]Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C: Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005, 60:788-794.
• [28]Zuberbier T, Lötvall J: Allergies have a socio-economic impact. European academy of allergology and clinical immunology, annual meeting 2008. Allergy 2008, 63(Suppl. 84):280.
• [29]Reed SD, Lee TA, McCrory DC: The economic burden of allergic rhinitis: a critical evaluation of the literature. PharmacoEconomics 2004, 22(6):345-361.
• [30]Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB: Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008, 63:1624-1629.
• [31]Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al.: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006, 354(19):1985-1997.
• [32]Marinho S, Simpson A, Custovic A: Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work? Prim Care Respir J. 2006, 15(3):152-158.
• [33]Phan H, Moeller ML, Nahata MC: Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs 2009, 69(18):2541-2576.
• [34]Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A: IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006, 368(9537):754-762.
• [35]White P, Smith H, Baker N, Davis W, Frew A: Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy. 1998, 28(3):266-270.
• [36]Allen DB: Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006, 53:101-110.
• [37]Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006, 29(10):897-909.
• [38]Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R, Price D, Bousquet J: ARIA update: I–Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006, 117(5):1054-1062.
• [39]Council of the European Union: Review of the EU Sustainable Developmental Strategy (EU SDS): Renewed Strategy. 2006. 10917/06
• [40]Abramson MJ, Puy RM, Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010, 4(8):CD001186.
• [41]Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 24(1):CD001936.
• [42]Radulovic S, Calderon MA, Wilson D, Durham S: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010, 8(12):CD002893.
• [43]Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR: Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011, 41(9):1263-1272.
• [44]Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341(7):468-475.
• [45]Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin Immunol. 2010, 125(1):131-138.
• [46]Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R: SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012, 129(3):717-725.
• [47]Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C, The PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62(8):943-948.
• [48]Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61(2):198-201.
• [49]Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004, 114(4):851-857.
• [50]Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G: Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010, 126(5):969-975.
• [51]Canonica GW, Bousquet J, Casale T, et al.: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl 91):1-59.
• [52]Noon L, Cantab BC: Prophylactic inoculation against hay fever. Lancet 1911, 177(4580):1572-1573.
• [53]Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998, 102(4 Pt 1):558-562.
• [54]Passalacqua G, Compalati E, Canonica GW: Advances in allergen-specific immunotherapy. Curr Drug Targets 2009, 10(12):1255-1262.
• [55]Bousquet PJ, Calderón MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Canonica GW, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, Schünemann HJ, Bousquet J: The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011, 127(1):49-56.
• [56]Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T: How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 2011, 66(6):765-774.
• [57]Calderón M, Cardona V, Demoly P: EAACI 100 Years of Immunotherapy Experts Panel. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012, 67(4):462-476.
• [58]Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P: Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011, 127(1):30-38.
• [59]Jacobsen L, Wahn U, Bilo MB: Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012, 2:8. BioMed Central Full Text